Aptamer Group to host technical development update webinar

Aptamer Group

Aptamer Group plc (LON:APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, has announced that Dr David Bunka, Chief Scientific Officer, will host a webinar to provide an update on the Company’s progress within its technical development programmes.

The webinar will be broadcast on Thursday, 14 August 2025, at 6:00 pm (BST) and will offer a detailed review of the latest data and technical developments, building on insights shared through recent regulatory announcements.

The webinar is open to shareholders and other interested parties who can register for the event by using the following link: https://www.turnerpope.com/register/

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

Aptamer Group secures £192k contracts with global pharma, boosting FY26 order book to £1.95m

Aptamer Group announced two new contracts worth £192,000, including a fourth engagement with a top five global pharmaceutical company and a new deal targeting acute myeloid leukaemia.

Aptamer Group reports strong FY2025 growth and expands Optimer® portfolio

Aptamer Group delivered strong progress in FY2025, achieving a 40% revenue increase and expanding its portfolio of licensable Optimer® assets from four to eleven.

Aptamer Group delivers 40% revenue growth and expands licensing portfolio

Aptamer Group has announced its full-year results for the twelve months ended 30 June 2025, delivering a 40% increase in revenue to £1.2 million and expanding its Optimer® licensing portfolio from four to eleven assets.

Aptamer Group secures repeat contract for Optimer® binder development

Aptamer Group has signed a new agreement with an existing partner to develop Optimer® binders targeting two proteins for biomarker research.

Aptamer Group to announce full year 2025 results on 14 October

Aptamer Group will publish results for the year ended 30 June 2025 on Tuesday, 14 October 2025, with an online analyst briefing at 9.30 am hosted by CEO Dr Arron Tolley and CFO Andrew Rapson. .

Aptamer Group secures £360,000 contract with top 3 global pharma

Aptamer Group has signed a £360,000 development contract with a leading global pharmaceutical company to engineer Optimer® binders as targeted radiopharmaceuticals.

    Search

    Search